» Articles » PMID: 26498282

Angiotensin-converting Enzyme 2 Inhibits High-mobility Group Box 1 and Attenuates Cardiac Dysfunction Post-myocardial Ischemia

Overview
Specialty General Medicine
Date 2015 Oct 27
PMID 26498282
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

High-mobility group box 1 (HMGB1) triggers and amplifies inflammation cascade following ischemic injury, and its elevated levels are associated with adverse clinical outcomes in patients with myocardial infarction (MI). Angiotensin-converting enzyme 2 (ACE2), a key member of vasoprotective axis of the renin-angiotensin system (RAS), regulates cardiovascular functions and exerts beneficial effects in cardiovascular disease. However, the association between HMGB1 and ACE2 has not been studied. We hypothesized that overexpression of ACE2 provides cardioprotective effects against MI via inhibiting HMGB1 and inflammation. ACE2 knock-in (KI) mice and littermate wild-type (WT) controls were subjected to either sham or coronary artery ligation surgery to induce MI. Heart function was assessed 4 weeks after surgery using echocardiography and Millar catheterization. Tissues were collected for histology and analysis of the expression of HMGB1, RAS components, and inflammatory cytokines. ACE2 in the heart of the ACE2 KI mice was 58-fold higher than WT controls. ACE2-MI mice exhibited a remarkable preservation of cardiac function and reduction of infarct size in comparison to WT-MI mice. Notably, ACE2 overexpression significantly reduced the MI-induced increase in apoptosis, macrophage infiltration, and HMGB1 and proinflammatory cytokine expression (TNF-α and IL-6). Moreover, in an in vitro study, ACE2 activation prevented the hypoxia-induced cell death and upregulation of HMGB1 in adult cardiomyocytes. This protective effect is correlated with downregulation of HMGB1 and downstream proinflammatory cascades, which could be useful for the development of novel treatment for ischemic heart disease.

Citing Articles

Targeting high-mobility-group-box-1-mediated inflammation: a promising therapeutic approach for myocardial infarction.

Date S, Bhatt L Inflammopharmacology. 2024; 33(2):767-784.

PMID: 39487941 DOI: 10.1007/s10787-024-01586-w.


The ACE2/Ang-(1-7)/MasR axis alleviates brain injury after cardiopulmonary resuscitation in rabbits by activating PI3K/Akt signaling.

Cheng J, Yang H, Qiu L, Chen F, Du Y, Meng X Transl Neurosci. 2024; 15(1):20220334.

PMID: 38623573 PMC: 11017183. DOI: 10.1515/tnsci-2022-0334.


Role of Angiotensin II in Cardiovascular Diseases: Introducing Bisartans as a Novel Therapy for Coronavirus 2019.

Swiderski J, Kate Gadanec L, Apostolopoulos V, Moore G, Kelaidonis K, Matsoukas J Biomolecules. 2023; 13(5).

PMID: 37238657 PMC: 10216788. DOI: 10.3390/biom13050787.


Evidence for Interplay Between the Renin-Angiotensin System and Toll-Like Receptor 4 Signaling Pathways in the Induction of Virus-Induced Acute Lung Injury.

Vogel S, Richard K, Shirey K, Sylla F, Boukhvalova M, Blanco J J Interferon Cytokine Res. 2022; 42(12):618-623.

PMID: 36206057 PMC: 9805881. DOI: 10.1089/jir.2022.0081.


High-mobility group box 1 (HMGB1) in COVID-19: extrapolation of dangerous liaisons.

Al-Kuraishy H, Al-Gareeb A, Alkazmi L, Habotta O, El-Saber Batiha G Inflammopharmacology. 2022; 30(3):811-820.

PMID: 35471628 PMC: 9040700. DOI: 10.1007/s10787-022-00988-y.


References
1.
Der Sarkissian S, Grobe J, Yuan L, Narielwala D, Walter G, Katovich M . Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension. 2008; 51(3):712-8. DOI: 10.1161/HYPERTENSIONAHA.107.100693. View

2.
Abdalla S, Lother H, Abdel-Tawab A, Quitterer U . The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem. 2001; 276(43):39721-6. DOI: 10.1074/jbc.M105253200. View

3.
Yamamoto K, Ohishi M, Katsuya T, Ito N, Ikushima M, Kaibe M . Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension. 2006; 47(4):718-26. DOI: 10.1161/01.HYP.0000205833.89478.5b. View

4.
Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Yamada S, Ueda Y . Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension. Am J Med Sci. 2011; 343(1):46-51. DOI: 10.1097/MAJ.0b013e31821f0552. View

5.
Kikuchi K, Tancharoen S, Ito T, Morimoto-Yamashita Y, Miura N, Kawahara K . Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. Int J Mol Sci. 2013; 14(9):18899-924. PMC: 3794813. DOI: 10.3390/ijms140918899. View